September 8, 2020 Sophia Vida
Biotech & Pharma

AbbVie Inc. Signs $2.9 Billion Deal with China’s I-Mab

Drugmaker AbbVie Inc. has inked a deal with Chinese drug developer I-Mab to collaborate on a cancer treatment. The deal could be worth a value of over $2.9 billion and gives Illinois-based AbbVie an exclusive global license to develop and sell I-Mab’s cancer-fighting drug lemzoparlimab outside of Greater China. Lemzoparlimab, also known as TJC4, is … Continue reading “AbbVie Inc. Signs $2.9 Billion Deal with China’s I-Mab”